Biopharmaceutical firm Immunomedics of Morris Plains, NJ, announced last month that the District Court in the Hague upheld the company's European patent when it dismissed a legal action brought by Hoffman LaRoche. Basil, Switzerland-based LaRoche filed
Biopharmaceutical firm Immunomedics of Morris Plains, NJ, announced last month that the District Court in the Hague upheld the company's European patent when it dismissed a legal action brought by Hoffman LaRoche. Basil, Switzerland-based LaRoche filed the action in response to an infringement suit Immunomedics brought against it last fall. Immunomedics' European patent is valid in nine countries and covers CEA-specific antibodies as well as immunoassays which use CEA antibodies, according to the company's patent attorney, Bernhard Saxe of Foley & Lardner in Washington, DC.
In other Immunomedics news, the company last month reported that it has conferred a royalty-bearing, nonexclusive license to Dako A/S of Glostrup, Denmark, for its worldwide patents covering antibodies to CEA. Dako will sell the antibodies to pathology laboratories that stain tumor specimens for CEA.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.